Journal: Cancers

Article Title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

doi: 10.3390/cancers17030490

Figure Lengend Snippet: Downstream effects of AXL and SRC in KRAS mutant NSCLC. ( a ) Western blot image showing protein expression of AXL- and SRC-related markers in AXL knockout A549 cells. ( b ) Western blot image showing protein expression for AXL and phospho-SRC in A549 cells treated with either siAXL, Dasatinib or both. ( c ) Western blot showing protein expression of KRAS and phospho-SHP2 (T542 and T580) in A549 cells before or after siAXL or knockout treatments. Increased expression in SHP2 activity is observed when AXL is inhibited. ( d ) Western blot image for downstream KRAS activity in A549 cells treated with either siAXL, Dasatinib or both.

Article Snippet: Dasatinib and AXL inhibitor, SGI-7079, were purchased from Selleck chemicals (Houston, TX, USA).

Techniques: Mutagenesis, Western Blot, Expressing, Knock-Out, Activity Assay

Journal: Cancers

Article Title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

doi: 10.3390/cancers17030490

Figure Lengend Snippet: Effect of co-inhibiting AXL and SRC in KRAS mutant NSCLC. ( a ) Western blot image for apoptotic proteins in A549 cells treated with either siAXL, Dasatinib or both. ( b ) Cytochrome-C assay for A549 cells; scale bar = 100 µm. ( c ) Cell-Death assay: Bright field Microscopy images (20×) for triggered cell death in A549 cells before or after either siAXL or DAS or treatment with both; scale bar = 200 µm. ( d ) Cell-Death assay: Bright field microscopy images (20×) of H460AK cells (i) before and (ii) after treatment with Dasatinib (DAS) for 48 h; scale bar = 200 µm. Results indicate higher cell death after DAS treatment in AXL knockout H460 cells.

Article Snippet: Dasatinib and AXL inhibitor, SGI-7079, were purchased from Selleck chemicals (Houston, TX, USA).

Techniques: Mutagenesis, Western Blot, Microscopy, Knock-Out

Journal: Cancers

Article Title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

doi: 10.3390/cancers17030490

Figure Lengend Snippet: Synergistic AXL and SRC therapy in vitro. ( a ) Dasatinib (IC 50 ) sensitization of NSCLC cell lines after co-inhibition of AXL + SRC using MTT assay (72 h). ( b ) Dasatinib (IC 50 ) sensitization of A549 and H460 cell lines comparing co-inhibition of AXL + SRC using siAXL or AXLi or CRISPR-knockout methods in an MTT assay (72 h). p -values are denoted by * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001) or **** ( p < 0.0001).

Article Snippet: Dasatinib and AXL inhibitor, SGI-7079, were purchased from Selleck chemicals (Houston, TX, USA).

Techniques: In Vitro, Inhibition, MTT Assay, CRISPR, Knock-Out

Journal: Cancers

Article Title: Synergistic Inhibition of Drug Resistant KRAS Mutant Non-Small Cell Lung Cancer by Co-Targeting AXL and SRC

doi: 10.3390/cancers17030490

Figure Lengend Snippet: Synergistic AXL and SRC therapy in vivo. ( a ) Tumor growth reduction in A549 xenografts treated with Dasatinib or combination of AXLi and Dasatinib ( b ) Corresponding graph showing tumor growth inhibition (%). ( c ) Tumor volume reduction plot for excised tumors. ( d ) Western blot image for DDR2, SHP2 and SRC activity in tumor lysates at the end of study. p -values are denoted by * ( p < 0.05), ** ( p < 0.01), *** ( p < 0.001) or **** ( p < 0.0001).

Article Snippet: Dasatinib and AXL inhibitor, SGI-7079, were purchased from Selleck chemicals (Houston, TX, USA).

Techniques: In Vivo, Inhibition, Western Blot, Activity Assay

Journal: iScience

Article Title: In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies

doi: 10.1016/j.isci.2023.108711

Figure Lengend Snippet:

Article Snippet: To assess the effectiveness of secondary therapies +/- osimertinib, cells were treated with increasing doses (log -10 – log -5 ; 0.1 nM – 10,000 nM) of crizotinib (S1068, Selleck Chemicals, Houston, TX, USA), cabozantinib (S1119, Selleck Chemicals, Houston, TX, USA), infigratinib (S2183, Selleck Chemicals, Houston, TX, USA), selpercatinib (S8781, Selleck Chemicals, Houston, TX, USA), linsitinib (S1091, Selleck Chemicals, Houston, TX, USA), SGI-7079 (S7847, Selleck Chemicals, Houston, TX, USA), dasatinib (S1021, Selleck Chemicals, Houston, TX, USA), or RMC-4550 (S8718, Selleck Chemicals, Houston, TX, USA) +/- 10 nM osimertinib.

Techniques: Recombinant, Protease Inhibitor, Phospho-proteomics, Software

Journal: iScience

Article Title: In situ modeling of acquired resistance to RTK/RAS-pathway-targeted therapies

doi: 10.1016/j.isci.2023.108711

Figure Lengend Snippet:

Article Snippet: SGI-7079 (AXL inhibitor) , Selleck Chemicals , S7847; CAS: 1239875-86-5.

Techniques: Recombinant, Protease Inhibitor, Software